vivo
dctarget
genet
immun
melanoma
antigenencod
dna
vaccin
induc
longlast
antimelanoma
immun
respons
day
post
melanoma
tumor
challeng
remark
memori
respons
month
second
tumor
challeng
avail
present
describ
cation
lipid
overcom
formid
challeng
induc
longlast
immun
respons
direct
vivo
target
tumor
antigenencod
dna
vaccin
dc
becom
feasibl
present
describ
direct
vivo
dctarget
liposom
dna
vaccin
carrier
thu
expect
find
futur
applic
effect
vaccin
develop
variou
infecti
diseas
cancer
result
cation
lipid
figur
contain
guanidinyl
lysin
spacer
hydrophob
tail
mannosemimick
shikimoyland
quinoyl
headgroup
well
mannosyl
analog
lipid
figur
synthes
convent
peptid
coupl
acetyl
protect
shikim
quinic
acid
mannos
appropri
derivat
lysinyl
amphiphil
follow
quatern
deprotect
chlorid
ion
exchang
supplementari
scheme
detail
synthet
scheme
procedur
nuclear
magnet
reson
nmr
mass
spectral
data
lipid
well
highperform
liquid
chromatographi
hplc
profil
purifi
lipid
two
differ
mobil
phase
provid
supplementari
inform
supplementari
figur
hydrodynam
diamet
zeta
size
liposom
formul
measur
dynam
light
scatter
techniqu
size
liposom
formul
lipid
within
rang
nm
supplementari
figur
lipoplex
lipid
lipid
dna
charg
ratio
found
within
rang
nm
supplementari
figur
major
limit
factor
retard
clinic
success
dendrit
cell
dc
base
genet
immun
dna
vaccin
scarciti
biolog
safe
effect
carrier
system
target
antigenencod
dna
vaccin
dc
vivo
set
herein
report
potent
mannos
receptor
select
vivo
dctarget
liposom
novel
cation
amphiphil
mannosemimick
shikimoyl
headgroup
flow
cytometr
experi
cell
isol
drain
lymph
node
mice
sc
immun
lipoplex
pgfp
plasmid
model
dna
vaccin
use
antibodylabel
magnet
bead
reveal
vivo
dctarget
properti
present
describ
liposom
dna
vaccin
carrier
importantli
sc
immun
mice
electrostat
complex
vivo
dctarget
liposom
melanoma
antigenencod
dna
vaccin
induc
longlast
antimelanoma
immun
respons
day
post
melanoma
tumor
challeng
remark
memori
respons
month
second
tumor
challeng
present
describ
direct
vivo
dctarget
liposom
dna
vaccin
carrier
expect
find
futur
exploit
toward
design
effect
vaccin
variou
infecti
diseas
cancer
dendrit
cell
dc
bodi
profession
antigenpres
cell
possess
uniqu
abil
captur
process
pathogen
antigen
peripher
blood
tissu
antigenload
dc
migrat
affer
lymphat
nearbi
drain
lymph
node
present
process
antigen
fragment
complex
classic
major
histocompat
complex
mhc
class
ii
nonclass
famili
antigenpres
molecul
rest
lymphocyt
distinguish
antigenpres
abil
dc
dc
pulsedtransduc
tumorassoci
viral
antigen
find
increas
applic
vaccin
cancer
infecti
diseas
dc
often
ex
vivo
transfect
tumorvir
antigensencod
dna
vaccin
ex
vivo
dc
transfectionbas
genet
immun
protocol
although
highli
effici
combat
cancer
laborintens
timeconsum
expens
autolog
dc
precursor
painstakingli
isol
isol
autolog
dc
precursor
ex
vivo
transfect
dna
vaccin
ex
vivo
transfect
dc
final
need
reimplant
recipi
bodi
mount
immun
respons
end
viral
nonvir
vector
use
direct
vivo
target
dna
vaccin
dc
howev
achiev
longlast
immun
use
simpl
costeffect
vivo
dctarget
system
remain
formid
challeng
previous
report
mannos
receptor
select
liposom
cation
amphiphil
contain
two
aliphat
nhexadecyl
nonpolar
tail
mannosemimick
shikimoyland
quinoylheadgroup
lysin
spacer
effici
dna
vaccin
carrier
ex
vivo
dc
transfectionbas
genet
immun
priorli
report
system
found
effici
induc
longlast
immun
respons
melanoma
mice
immun
dc
ex
vivo
transfect
lipoplex
melanoma
antigenencod
dna
vaccin
howev
describ
system
fail
mount
longlast
immun
respons
melanoma
use
direct
vivo
dctarget
mode
envisag
dc
transfect
effici
new
class
mannos
receptor
select
lipid
contain
mannosemimick
shikimoyland
quinoylheadgroup
need
enhanc
make
liposom
effect
target
dna
vaccin
dc
vivo
set
rational
mind
present
studi
chemic
transform
lysin
side
chain
amino
group
transfect
enhanc
guanidin
group
herein
show
liposom
cation
amphiphil
contain
mannosemimick
shikimoyl
headgroup
two
nhexadecyl
hydrophob
tail
target
dna
vaccin
dc
vivo
set
side
chain
amino
group
lysin
spacer
guanidinyl
lipid
figur
show
direct
vivo
immun
sc
mice
electrostat
complex
liposom
lipid
primari
mbmdc
mous
bone
marrowderiv
dc
isol
bone
marrow
tibia
fibula
male
mice
describ
previous
distinguish
dc
surfac
marker
includ
mhc
ii
total
mhc
ii
mannos
receptor
isol
mbmdc
confirm
flow
cytometri
supplementari
figur
first
evalu
dc
transfect
properti
liposom
lipid
flow
cytometri
use
gfp
plasmid
model
dna
vaccin
first
transfect
mbmdc
gfp
plasmid
complex
liposom
lipid
equimolar
dope
colipid
cation
lipid
dna
charg
ratio
initi
transfect
experi
across
rang
lipid
dna
charg
ratio
reveal
optim
lipid
dna
charg
ratio
data
shown
transfect
cell
visual
fluoresc
microscopi
figur
rel
transfect
effici
lipid
measur
flow
cytometri
figur
flow
cytometr
measur
transfect
effici
autofluoresc
intens
untreat
control
cell
subtract
fluoresc
intens
treat
cell
lipoplex
lipid
mannosemimick
shikimoyl
headgroup
found
effici
dc
transfect
effici
follow
liposom
lipid
dc
transfect
effici
respect
figur
commerci
avail
lipofectamin
found
poor
transfect
mbmdc
figur
c
mannos
receptor
select
dc
transfect
properti
lipid
significantli
affect
mbmdc
preincub
mgml
mannan
natur
ligand
mannos
receptor
figur
support
notion
dc
transfect
lipid
mediat
via
mannos
receptor
furthermor
toward
address
concentrationdepend
inhibit
mannan
evalu
dc
transfect
effici
lipid
use
dc
preincub
increas
mannan
concentr
across
mgml
dc
transfect
effici
advers
affect
increas
concentr
mannan
supplementari
figur
importantli
dc
transfect
properti
lipid
significantli
affect
dc
preincub
laminarin
commerci
avail
polysaccharid
glucos
supplementari
figur
thu
find
summar
figur
supplementari
figur
b
convincingli
demonstr
mannos
receptormedi
dc
transfect
efficaci
cation
amphiphil
mannosemimick
shikimoyl
quinoylheadgroup
confirm
mannos
receptorspecif
vitro
dc
transfect
effici
lipid
measur
effici
liposom
formul
lipid
contain
equimolar
dope
target
dna
vaccin
dc
vivo
condit
use
pcmvgfp
model
dna
vaccin
lipoplex
liposom
dna
complex
lipid
inject
sc
mice
twentyfour
hour
inject
percentag
gfpposit
cell
cell
isol
lymph
node
use
antibodylabel
magnet
bead
describ
previous
mice
inject
vehicl
glucos
solut
use
control
find
flow
cytometr
studi
reveal
significantli
higher
number
gfpposit
cell
drain
lymph
node
cell
mice
inject
lipoplex
lipid
compar
correspond
number
observ
mice
inject
lipoplex
lipid
figur
b
also
evalu
express
level
transfect
dc
vivo
condit
use
flow
cytometr
method
inject
mice
n
lipoplex
lipid
find
summar
supplementari
figur
clearli
show
liposom
lipid
effici
among
lipid
target
dna
vaccin
dc
vivo
condit
use
nontransfect
dc
control
next
assess
rel
phenotyp
chang
dc
transfect
promis
lipoplex
lipid
liposom
lipid
express
level
dc
matur
marker
signific
dc
transfect
lipoplex
lipid
induc
figur
importantli
dc
treat
liposom
lipid
plasmid
fail
show
signific
phenotyp
matur
figur
view
gain
insight
natur
cytokin
secret
transfect
dc
use
elisa
kit
measur
cytokin
level
supernat
transfect
experi
cell
use
cell
transfect
lipoplex
lipid
plasmid
contain
lipid
dna
charg
ratio
degre
gfp
express
transfect
mbmdc
visual
use
epifluoresc
microscop
quantifi
flow
cytometri
transfect
effici
case
also
measur
use
gfp
lipoplex
commerci
avail
liposom
transfect
kit
lipofectamin
extrem
right
panel
experi
repeat
three
time
transfect
profil
found
similar
time
lipofect
presat
mannan
lipid
presat
mannan
lipid
presat
mannan
lipid
presat
mannan
lipofect
presat
mannan
presat
mannan
presat
mannan
lipofect
toward
confirm
sc
immun
lipoplex
lipid
mice
capabl
induc
immun
respons
vivo
set
first
use
plasmid
model
dna
vaccin
mice
sc
immun
complex
liposom
lipid
equimolar
dope
two
week
post
third
immun
splenocyt
sera
collect
signatur
cytokin
cellular
immun
respons
antibodi
humor
immun
respons
measur
use
elisa
plate
respect
mice
immun
vehicl
glucos
use
control
importantli
amount
measur
splenocyt
amount
antibodi
measur
sera
mice
group
immun
lipoplex
lipid
found
significantli
higher
control
mice
group
well
mice
group
immun
lipoplex
lipid
supplementari
figur
b
initi
find
prompt
us
conduct
vivo
dctarget
genet
immun
experi
use
lipoplex
lipid
contain
shikimoylheadgroup
dna
vaccin
encod
human
share
amino
acid
sequenc
ident
murin
counterpart
first
mice
n
immu
experi
describ
show
immun
lipoplex
lipid
effici
protect
mice
subsequ
tumor
challeng
view
evalu
efficaci
lipoplex
therapeut
set
lipoplex
lipid
sc
administ
mice
bear
establish
tumor
sixto
eightweekold
femal
mice
weigh
g
n
sc
inject
cell
right
figur
b
show
mice
group
immun
lipoplex
lipid
effici
inhibit
tumor
growth
compar
mice
group
treat
correspond
lipoplex
lipid
overal
surviv
tumorbear
mice
group
immun
lipoplex
lipid
day
also
higher
tumorbear
mice
group
immun
correspond
lipoplex
lipid
figur
next
toward
probe
rel
contribut
humor
cellular
immun
respons
perform
convent
cytotox
lymphocyt
ctl
assay
measur
amount
secret
signatur
cytokin
cellular
humor
immun
respons
respect
supernat
cocultur
effector
cell
splenocyt
isol
immun
mice
target
melanoma
cell
lysi
target
melanoma
cell
prime
splenocyt
studi
across
effector
target
cell
ratio
importantli
effector
splenocyt
isol
mice
immun
lipoplex
lipid
lyse
target
melanoma
cell
significantli
reduc
target
cell
lysi
could
effect
splenocyt
isol
mice
immun
lipoplex
lipid
control
irrelev
plasmid
figur
show
mice
group
immun
vivo
dctarget
lipoplex
lipid
effici
induc
ctl
respons
target
cell
consist
target
cell
select
lytic
activ
effector
splenocyt
result
cytokin
secret
assay
also
reveal
remark
higher
amount
compar
secret
secret
activ
cell
figur
c
distinguish
marker
cellular
immun
respons
result
shown
figur
c
consist
supposit
cellmedi
immun
play
crucial
role
behind
present
observ
remark
antitumor
immun
respons
two
group
mice
n
group
immun
thrice
lipoplex
lipid
day
first
group
receiv
ip
inject
mab
day
second
immun
group
receiv
mab
third
unimmun
group
inject
aqueou
glucos
vehicl
control
group
three
group
challeng
cell
day
first
two
group
tumor
growth
measur
slide
calip
mice
group
receiv
mab
live
tumorfre
live
immun
lipoplex
lipid
five
member
unimmun
control
mice
group
develop
tumor
within
day
figur
importantli
four
five
mice
immun
deplet
cell
develop
tumor
upon
challeng
tumor
cell
figur
find
convincingli
demonstr
cellmedi
cell
immun
play
critic
role
induc
antitumor
immun
respons
present
describ
vivo
dctarget
liposom
dna
vaccin
carrier
dna
vaccin
ie
use
nake
plasmid
dna
vaccin
prime
immun
system
offer
number
practic
benefit
easili
achiev
exist
form
vaccin
attenu
virus
subunit
recombin
protein
vaccin
whole
tumor
cell
etc
number
distinct
advantag
use
pdna
genet
immun
easi
design
construct
largescal
product
costeffect
contrast
attenu
viral
vaccin
whose
storag
global
deliveri
complic
need
keep
vaccin
cold
plasmid
dna
fairli
stabl
room
temperatur
sinc
antigen
encod
dna
vaccin
express
situ
posttransl
modif
happen
similar
way
case
infect
cognat
pathogen
anoth
distinguish
featur
dna
vaccin
immun
respons
induc
genet
immun
often
primarili
cellular
natur
believ
play
crucial
role
effect
vaccin
pathogen
eg
virus
cancer
despit
distinguish
advantag
low
vivo
cell
transfect
effici
nake
plasmid
dna
difficulti
preferenti
target
dna
vaccin
profession
antigenpres
cell
dc
modest
intrins
adjuv
activ
dna
vaccin
imped
clinic
success
end
immun
autolog
dc
ex
vivo
transfect
antigenencod
dna
vaccin
shown
promis
past
ex
vivo
dc
transfectionbas
immun
protocol
laborintens
timeconsum
expens
patientfriendli
aim
resolv
abovement
problem
associ
ex
vivo
dc
transfectionbas
protocol
genet
immun
global
effort
begun
toward
develop
protocol
direct
vivo
target
antigenencod
dna
vaccin
dc
promis
recent
develop
strategi
direct
vivo
target
dna
vaccin
dc
includ
use
antibodi
target
dcspecif
receptor
includ
etc
deliv
encod
antigen
use
dcspecif
promot
eg
express
cytokin
requir
enhanc
vaccin
efficaci
daftarian
et
al
show
use
fifthgener
polyamidoamin
dendrim
possess
dnaload
surfac
coval
graft
mhc
class
iitarget
peptid
univers
dna
platform
vivo
dctarget
genet
vaccin
encod
cytomegaloviru
cmv
driven
vaccin
dcspecif
activ
transcript
factor
shown
induc
prophylact
therapeut
antitumor
immun
raghuwanshi
et
al
recent
succeed
develop
vivo
dctarget
chitosan
nanoparticl
nasal
dna
immun
nucleocapsid
n
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
antigen
cao
et
al
construct
vivo
dctarget
dna
vaccin
fuse
tumorassoci
antigen
ectodomain
singl
chain
antibodi
fragment
scfv
antibodi
specif
dcrestrict
surfac
molecul
demonstr
potent
antitumor
cellular
humor
immun
respons
induc
efficaci
raviv
et
al
demonstr
mannosyl
polyion
complex
safe
effect
system
vivo
target
gene
dc
import
emphas
previous
report
liposom
cation
lipid
contain
mannosemimick
shikimoyland
quinoylheadgroup
pure
lysin
spacer
ie
without
lysin
side
chain
amin
group
guanidinyl
case
present
describ
lipid
figur
capabl
mount
longlast
immun
respons
ex
vivo
dc
transfectionbas
dna
vaccin
dc
hardtotransfect
although
dc
transfect
efficaci
previous
report
lipid
contain
pure
lysin
spacer
mannosemimick
headgroup
hydrophob
tail
lipid
fail
mount
longlast
immun
respons
melanoma
challeng
use
direct
vivo
immun
mode
supplementari
figur
sinc
prior
studi
demonstr
effici
gene
transfer
properti
guanidinyl
cation
amphiphil
decid
convert
amin
group
lysin
side
chain
previous
report
lipid
guanidin
group
use
convent
guanidinyl
reagent
hgcl
n
ndibocthiourea
number
distinguish
chemic
characterist
contribut
enhanc
gene
transfer
effici
guanidinyl
cation
amphiphil
guanidinium
group
high
pka
valu
remain
proton
across
much
wider
rang
ph
compar
basic
group
therebi
exhibit
strong
electrostat
bind
properti
phosphat
group
macromolecular
dna
molecul
physiolog
ph
addit
form
characterist
parallel
zwitterion
nh
hydrogen
bond
phosphat
ion
dna
molecul
form
hydrogen
bond
nucleic
acid
base
vitro
vivo
dc
transfect
studi
clearli
demonstr
lipid
effici
compar
lipid
hydrodynam
diamet
liposom
lipid
found
within
rang
nm
supplementari
figur
correspond
rang
lipoplex
lipid
within
nm
supplementari
figur
similar
hydrodynam
diamet
lipoplex
lipid
consist
supposit
size
lipoplex
unlik
play
major
role
modul
dc
transfect
effici
lipid
understand
increas
ex
vivo
dc
transfect
effici
case
previou
report
lipid
convers
lysin
amino
side
chain
guanidin
present
studi
impart
vivo
dctarget
abil
lipid
perhap
minimum
threshold
ex
vivo
dc
transfect
effici
impart
vivo
dctarget
abil
cation
lipid
lie
near
howev
deciph
threshold
ex
vivo
dc
transfect
cation
lipid
would
imposs
find
without
indepth
futur
structureact
studi
use
number
structur
analog
use
multipl
shikimoyland
quinoylheadgroup
use
multipl
guanidin
group
headgroup
region
etc
import
issu
worth
mention
point
discuss
although
present
studi
demonstr
vivo
dctarget
abil
mannos
receptorspecif
lipoplex
lipid
present
find
preclud
possibl
macrophag
possibl
myeloid
cell
mani
express
mannos
receptor
cell
surfac
transfect
lipoplex
lipid
sinc
dc
potent
antigenpres
cell
mount
adapt
immun
respons
herein
primari
focu
vivo
dctransfect
abil
present
describ
lipid
clue
yet
origin
dctarget
efficaci
lipoplex
lipid
compar
lipoplex
lipid
issu
remain
elus
stage
investig
clearli
mechanist
studi
bind
studi
use
purifi
mannos
receptor
need
undertaken
futur
toward
gain
insight
rel
vivo
dctarget
efficaci
lipoplex
lipid
despit
signific
recent
progress
emerg
field
vivo
dctarget
genet
immun
challeng
design
simpl
safe
effect
system
vivo
target
dna
vaccin
dc
remain
formid
end
use
syngen
mous
melanoma
model
shown
immun
tumor
antigen
encod
dna
vaccin
complex
present
describ
nextgener
liposom
dna
vaccin
carrier
capabl
mount
longlast
immun
respons
lethal
dose
melanoma
tumor
challeng
five
immun
mice
live
complet
tumorfre
live
day
post
first
tumor
challeng
dna
vaccin
encod
kda
human
melana
antigen
share
amino
acid
sequenc
ident
murin
counterpart
human
melanocyt
lineagespecif
antigen
express
major
human
malign
melanoma
effect
antigenspecif
immun
ensu
dc
present
process
antigen
fragment
cell
dc
present
process
antigen
fragment
cell
complex
mhc
ii
molecul
caus
differenti
cell
thelper
thelper
cell
induc
cellular
humor
immun
respons
respect
dc
present
process
protein
fragment
cell
complex
mhc
molecul
activ
cell
differenti
ctl
effector
cell
kill
affect
cell
help
cell
importantli
present
studi
mice
live
complet
tumorfre
live
day
first
tumor
challeng
live
complet
tumorfre
live
day
post
second
tumor
challeng
precis
mechan
longlast
immun
respons
melanoma
antigen
induc
present
figur
b
anoth
import
issu
deserv
mention
point
prior
studi
show
lipoplex
gener
effect
block
tumor
growth
mice
due
capabl
induc
acut
immun
respons
find
ctl
assay
summar
figur
clearli
show
target
cell
lysi
happen
extent
splenocyt
e
ratio
mice
immun
control
lipoplex
lipid
plasmid
control
dna
vaccin
encod
tumor
antigen
contrastingli
degre
target
cell
lysi
splenocyt
mice
immun
lipoplex
lipid
dna
vaccin
found
shown
figur
consist
find
ctl
assay
amount
secret
marker
cellular
immun
respons
marker
humor
immun
respons
mice
immun
lipid
pcmv
lipoplex
found
seven
time
higher
amount
secret
mice
immun
control
lipoplex
lipid
plasmid
figur
c
base
assay
perform
week
immun
thu
nonspecif
immun
respons
induc
properti
lipoplex
unlik
play
major
role
present
describ
longlast
immun
respons
furthermor
find
newli
conduct
experi
use
deplet
mice
figur
clearli
support
notion
cell
play
import
mount
longlast
immun
respons
describ
herein
state
differ
result
summar
supplementari
figur
b
figur
c
convincingli
demonstr
heighten
cellular
immun
respons
play
crucial
role
behind
remark
sustain
protect
immun
melanoma
tumor
describ
herein
shown
liposom
cation
amphiphil
contain
mannosemimick
shikimoylheadgroup
two
nhexadecyl
hydrophob
tail
guanidinyl
lysin
spacer
mannosemimick
headgroup
nonpolar
tail
hold
great
promis
direct
vivo
target
tumor
antigenencod
dna
vaccin
dc
design
dcbase
cancer
vaccin
avail
present
describ
simpl
liposom
vivo
dctarget
system
avoid
potenti
unsaf
viral
vector
target
dc
vivo
set
genet
immun
feasibl
dramat
longlast
primari
immun
respons
melanoma
immun
mice
remark
memori
respons
delin
herein
support
futur
system
promis
present
describ
direct
vivo
dctarget
liposom
dna
vaccin
carrier
combat
cancer
potenti
mani
challeng
infecti
diseas
known
pathogen
antigen
direct
dna
vaccin
anim
human
bodi
gener
procedur
materi
reagent
lcq
ion
trap
mass
spectromet
thermofinnigan
san
jose
ca
equip
esi
sourc
micromass
quattro
lc
tripl
quadrapol
mass
spectromet
use
esi
mass
spectral
analysi
target
lipid
varian
ft
mhz
mhz
nmr
spectromet
use
run
nmr
spectra
target
lipid
synthet
intermedi
quinic
shikim
acid
use
synthesi
lipid
fluka
switzerland
dmannos
use
synthesi
lipid
sd
fine
chemic
hyderabad
india
edci
hobt
use
coupl
qunic
shikim
acid
tertiari
amin
intermedi
procur
sigmaaldrich
st
loui
mo
silica
gel
mesh
use
perform
column
chromatographi
purchas
acm
synthet
chemic
mumbai
india
revers
phase
analyt
hplc
analysi
use
two
differ
mobil
phase
pure
methanol
b
vv
methanolwat
use
conform
puriti
target
lipid
plasmid
dna
use
present
studi
kind
gift
dr
van
den
eynd
ludwig
institut
cancer
research
brussel
belgium
dr
nalam
madhusudhana
rao
kindli
provid
us
sampl
plasmid
ctl
assay
kit
elisa
kit
cytokin
assay
procur
thermo
scientif
waltham
promega
madison
ca
mous
fitcconjug
mannos
receptor
antibodi
purchas
biolegend
san
diego
ca
mous
phycoerythrinconjug
fitcconjug
antibodi
purchas
cell
signal
danver
mous
antimhc
ii
monoclon
antibodi
use
chemicon
billerica
mab
purchas
pierc
biotechnolog
rockford
elisa
kit
procur
r
system
minneapoli
mn
antibodylabel
magnet
bead
midimax
column
purchas
miltenyi
biotec
bergisch
gladbach
germani
cholesterol
cell
cultur
media
fetal
bovin
serum
fitcconjug
rat
antimous
secondari
antibodi
purchas
sigmaaldrich
antibiot
agaros
obtain
himedia
india
murin
melanoma
cell
procur
nation
centr
cell
scienc
ncc
pune
india
dulbecco
modifi
eagl
medium
fetal
bovin
serum
use
cultur
cell
humidifi
atmospher
contain
co
air
mice
weigh
g
week
old
obtain
nation
institut
nutrit
hyderabad
india
vivo
experi
done
follow
institut
biosafeti
ethic
committe
guidelin
use
approv
anim
protocol
colipid
dope
lipid
mole
ratio
dissolv
chloroform
solvent
result
homogen
solut
remov
thin
stream
nitrogen
ga
residu
dri
high
vacuum
hour
vacuum
dri
residu
upon
hydrat
deioniz
water
overnight
afford
vivo
dctarget
liposom
appropri
weight
lipid
dope
use
result
liposom
contain
mmoll
lipid
mmoll
dope
vitro
experi
correspond
concentr
mmoll
vivo
experi
hydrat
lipid
film
briefli
vortex
second
thereaft
sonic
clariti
use
branson
sonifi
duti
cycl
w
output
power
result
clear
aqueou
liposom
complex
plasmid
dna
prepar
lipoplex
hydrodynam
diamet
liposom
lipoplex
lipid
use
dna
analyz
dynam
light
scatter
perform
dynapro
nano
dynam
light
scatter
system
wyatt
technolog
santa
barbara
ca
measur
perform
fix
angl
room
temperatur
isol
primari
mbmdc
mbmdc
isol
tibia
fibula
mice
describ
previous
briefli
bone
marrow
collect
tibia
fibula
male
mice
bone
debri
collect
bone
marrow
remov
pass
nylon
mesh
pass
cell
resuspend
complet
dc
medium
contain
fetal
bovin
serum
mmoll
glutamin
nonessenti
amino
acid
ngml
granulocytemacrophag
colonystimul
factor
ngml
antibiot
solut
cell
media
chang
everi
day
fresh
dc
medium
aggreg
cell
dislodg
gentli
pipet
rpmi
day
dislodg
cell
pull
togeth
centrifug
minut
room
temperatur
supernat
discard
pellet
resuspend
complet
dc
medium
cellsml
resuspend
cell
place
cell
cultur
petri
dish
cellsdish
use
ml
medium
per
dish
nonadher
cell
collect
hour
gentli
swirl
dish
use
transfect
flow
cytometri
experi
cultur
collect
nonadher
dc
maintain
humidifi
atmospher
co
fac
protocol
cell
fix
formaldehyd
solut
hour
centrifug
supernat
discard
pellet
cell
suspend
ml
wash
buffer
phosphatebuff
salin
pb
contain
fetal
bovin
serum
sodium
azid
incub
min
cell
suspens
divid
equal
eppendorf
tube
contain
cell
tube
centrifug
supernat
discard
final
cell
pellet
tube
commerci
avail
phycoerythrinlabel
mous
monoclon
antibodi
dilut
wash
buffer
ad
wash
buffer
ad
one
tube
control
cell
suspens
cultur
room
temperatur
hour
centrifug
supernat
discard
cell
pellet
wash
wash
buffer
ml
wash
cell
incub
hour
sequenti
addit
commerci
avail
unlabel
antimhc
ii
monoclon
antibodi
dilut
fitcconjug
secondari
antibodi
dilut
measur
mhc
ii
marker
profil
sequenc
centrifug
wash
repeat
three
time
final
cell
pellet
suspend
ml
wash
buffer
flow
cytometri
histogram
record
facscalib
instrument
becton
dickinson
franklin
lake
nj
cell
permeabil
methanol
minut
incub
antibodi
measur
total
mhc
ii
express
dc
gfp
express
transfect
mbmdc
measur
flow
cytometri
harvest
wash
transfect
cell
wash
buffer
wash
pellet
suspend
ml
wash
buffer
flow
cytometri
histogram
record
use
untreat
mbmdc
control
phenotyp
analysi
transfect
dc
perform
use
fitclabel
monoclon
antibodi
describ
elisa
antibodi
antibodi
measur
use
elisa
describ
previous
assay
measur
cytokin
perform
describ
previous
two
week
third
immun
mice
sacrif
spleen
isol
minc
spleen
syring
plunger
erythrocyt
lyse
ml
lysi
buffer
moll
ammonium
chlorid
moll
trishcl
ph
viabl
cell
count
hemocytomet
use
assay
elisa
day
stimul
target
cell
follow
manufactur
protocol
endogen
mous
elisa
kit
mous
elisa
kit
pierc
biotechnolog
briefli
splenocyt
complet
medium
ad
plate
precoat
antimous
antimous
antibodi
cellswel
incub
hour
presenc
co
incub
cell
wash
wash
buffer
biotinyl
secondari
antibodi
ad
well
mixtur
incub
hour
room
temperatur
wash
wash
buffer
wash
cell
next
incub
streptavidinhors
radish
peroxidas
solut
minut
wash
wash
buffer
treat
substrat
solut
mixtur
incub
minut
dark
reaction
stop
ad
stop
solut
well
absorb
read
micropl
reader
nm
phenotyp
analysi
cell
splenocyt
lymph
node
immun
mice
singlecel
suspens
spleen
cell
lymph
node
prepar
mice
day
third
immun
cell
stain
fitcconjug
monoclon
antibodi
phycoerythrinconjug
monoclon
antibodi
analyz
flow
cytometri
cell
collect
spleen
lymph
node
mice
immun
vehicl
use
control
ctl
assay
ctl
assay
perform
describ
previous
briefli
singlecel
suspens
splenocyt
prepar
mice
day
third
immun
cell
seed
onto
plate
cellswel
cocultur
cell
cellswel
rpmi
complet
medium
contain
uml
antibiot
solut
sigmaaldrich
uml
thermo
scientif
hour
appropri
number
result
effector
e
cell
incub
fresh
target
cell
e
ratio
vari
within
well
ubottom
plate
mixtur
incub
hour
co
final
lactat
dehydrogenas
level
cell
cultur
supernat
measur
ctl
assay
kit
follow
manufactur
promega
instruct
vivo
tcell
deplet
studi
two
group
mice
n
group
immun
thrice
lipoplex
lipid
day
first
group
receiv
ip
inject
mab
day
second
immun
group
receiv
mab
third
unimmun
group
inject
aqueou
glucos
vehicl
control
group
day
three
group
challeng
cell
day
tumor
growth
measur
slide
calip
statist
analysi
data
repres
mean
sd
individu
treatment
group
compar
control
untreat
group
use
student
ttest
p
consid
signific
scheme
synthesi
lipid
scheme
synthesi
lipid
scheme
synthesi
control
mannosyl
lipid
figur
h
nmr
mhz
cdcl
cd
od
spectrum
lipid
figur
esi
mass
spectrum
lipid
figur
h
nmr
mhz
cdcl
cd
od
spectrum
lipid
figur
esi
mass
spectrum
lipid
figur
h
nmr
mhz
cd
od
spectrum
lipid
figur
esi
mass
spectra
lipid
figur
repres
hplc
chromatogram
lipid
use
pure
methanol
mobil
phase
use
methanol
water
vv
mobil
phase
b
figur
repres
hplc
chromatogram
lipid
use
pure
methanol
mobil
phase
use
methanol
water
vv
mobil
phase
b
figur
repres
hplc
chromatogram
lipid
use
pure
methanol
mobil
phase
use
methanol
water
vv
mobil
phase
b
figur
hydrodynam
diamet
liposom
formul
lipid
figur
hydrodynam
diamet
lipoplex
lipid
lipid
dna
charg
ratio
presenc
serum
free
rpmi
medium
figur
confirm
presenc
dc
surfac
marker
flow
cytometri
figur
lipid
transfect
dc
via
mannos
receptor
figur
express
transfect
dc
vivo
lipoplex
lipid
figur
immun
lipoplex
lipid
produc
cellular
humor
immun
respons
mice
figur
immun
lipoplex
lipid
less
effici
protect
syngen
mice
lethal
melanoma
challeng
figur
liposom
previous
describ
cation
lipid
contain
mannosemimick
headgroup
pure
lysin
spacer
sriniva
r
et
al
biomateri
capabl
mount
longlast
immun
respons
ex
vivo
dctransfect
base
dna
vaccin
mode
direct
vivo
immun
lipoplex
figur
immun
sc
mice
lipoplex
lipid
lipid
significantli
enhanc
popul
cell
mous
splenocyt
lymph
node
